Several analysts have recently updated their ratings and price targets for Valeant Pharmaceuticals International (NYSE: VRX):

  • 9/20/2016 – Valeant Pharmaceuticals International is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $30.00 price target on the stock.
  • 9/20/2016 – Valeant Pharmaceuticals International had its “sector perform” rating reaffirmed by analysts at RBC Capital Markets.
  • 9/18/2016 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Co..
  • 9/7/2016 – Valeant Pharmaceuticals International had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $42.00 price target on the stock.
  • 9/7/2016 – Valeant Pharmaceuticals International had its “sector perform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $36.00 price target on the stock.
  • 8/29/2016 – Valeant Pharmaceuticals International had its “sector perform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $36.00 price target on the stock.
  • 8/26/2016 – Valeant Pharmaceuticals International had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $42.00 price target on the stock.
  • 8/22/2016 – Valeant Pharmaceuticals International had its “positive” rating reaffirmed by analysts at Deutsche Bank AG.
  • 8/19/2016 – Valeant Pharmaceuticals International had its “positive” rating reaffirmed by analysts at Morgan Stanley.
  • 8/19/2016 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $33.00 price target on the stock, up previously from $31.00.
  • 8/19/2016 – Valeant Pharmaceuticals International was given a new $36.00 price target on by analysts at RBC Capital Markets. They now have a “hold” rating on the stock.
  • 8/19/2016 – Valeant Pharmaceuticals International was given a new $22.00 price target on by analysts at Piper Jaffray Cos.. They now have a “sell” rating on the stock.
  • 8/18/2016 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Mizuho. They now have a $11.00 price target on the stock.
  • 8/17/2016 – Valeant Pharmaceuticals International was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $42.00 price target on the stock, up previously from $33.00.
  • 8/16/2016 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Co.. They now have a $19.50 price target on the stock.
  • 8/16/2016 – Valeant Pharmaceuticals International was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Valeant’s lower-than-expected earnings in the second-quarter of 2016 were disappointing. Quarterly revenues were impacted by lower product sales from existing businesses and negative foreign exchange fluctuations. Valeant also incurred high R&D expenses due to development programs related to its dermatology portfolio, spending related to brodalumab, and programs acquired through the Salix acquisition. Nevertheless, the company has been active on the acquisition front over the last few years, which has been driving growth. Valeant’s efforts in venturing into the gastrointestinal disease & Women's Health Markets are also encouraging. However, Valeant has been in the spotlight since Aug 2015 for all the wrong reasons like a price hike of specialty drugs, erroneous financial reporting, and termination of contracts with Philidor Rx Services.”
  • 8/15/2016 – Valeant Pharmaceuticals International was upgraded by analysts at Mizuho from an “underperform” rating to a “neutral” rating. They now have a $25.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/13/2016 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at TD Securities. They now have a $38.00 price target on the stock.
  • 8/11/2016 – Valeant Pharmaceuticals International had its “sector perform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $31.00 price target on the stock.
  • 8/11/2016 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $55.00 price target on the stock.
  • 8/11/2016 – Valeant Pharmaceuticals International was upgraded by analysts at Mizuho from an “underperform” rating to a “neutral” rating. They now have a $25.00 price target on the stock.
  • 8/10/2016 – Valeant Pharmaceuticals International had its price target raised by analysts at Royal Bank Of Canada from $31.00 to $36.00. They now have a “sector perform” rating on the stock.
  • 8/10/2016 – Valeant Pharmaceuticals International had its price target raised by analysts at Piper Jaffray Cos. from $19.00 to $22.00. They now have an “underweight” rating on the stock.
  • 8/10/2016 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $40.00 price target on the stock. They wrote, “VRX missed cons revs & EPS ests by 2% & 5% as the US derm/GI businesses remained sluggish. That said, EPS grew 10% Q/Q to reach $2.66 (39% of FY16 guidance). And there were some encouraging signs – with mgt delivering cost efficiencies, paying down another $880M in debt, selling modest sized non- core assets, deploying new initiatives to improve its derm/GI businesses, and offering a realistic pathway towards reaching debt obligations through 2017. 2016 Guidance Unchanged and It Remains Back Loaded; Can Mgt Deliver Despite Some Clear Headwinds?: Despite the Q2 miss relative to consensus, mgt maintained its full year rev & EPS guidance of $9.9-10.1B and $6.60-$7.00. Mgt cited 2H tailwinds from seasonality (e.g., derm), expectations of improved performance in US dermatology and GI following recent initiatives, front loaded R&D spend, and improved cost efficiencies as key reasons. Moreover, they expect to reach these targets despite the ongoing genericization of Ziana and Zegerid and likely loss of exclusivity to Nitropress in 4Q16.””
  • 8/10/2016 – Valeant Pharmaceuticals International had its “neutral” rating reaffirmed by analysts at BTIG Research.
  • 8/10/2016 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $28.00 price target on the stock.
  • 8/10/2016 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Co.. They now have a $19.50 price target on the stock.
  • 8/9/2016 – Valeant Pharmaceuticals International had its price target lowered by analysts at Rodman & Renshaw from $90.00 to $81.00. They now have a “buy” rating on the stock.
  • 8/3/2016 – Valeant Pharmaceuticals International was given a new $33.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
  • 8/1/2016 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Co.. They now have a $19.50 price target on the stock.
  • 8/1/2016 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $28.00 price target on the stock.
  • 7/28/2016 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Rodman & Renshaw. They now have a $90.00 price target on the stock.
  • 7/26/2016 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Mizuho. They now have a $11.00 price target on the stock.
  • 7/26/2016 – Valeant Pharmaceuticals International had its “sector perform” rating reaffirmed by analysts at Scotiabank. They now have a $32.00 price target on the stock, down previously from $35.00.
  • 7/25/2016 – Valeant Pharmaceuticals International was given a new $35.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “hold” rating on the stock.

Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) opened at 26.97 on Thursday. The firm’s 50-day moving average price is $27.82 and its 200-day moving average price is $29.11. Valeant Pharmaceuticals International Inc. has a 12 month low of $18.55 and a 12 month high of $217.07. The firm’s market cap is $9.37 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing analysts’ consensus estimates of $1.48 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same quarter last year, the company earned $2.14 earnings per share. The firm’s revenue for the quarter was down 11.4% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals International Inc. will post $6.53 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/recent-analysts-ratings-changes-for-valeant-pharmaceuticals-international-vrx.html

In other news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were bought at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the purchase, the director now directly owns 20,726 shares of the company’s stock, valued at $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 16.37% of the company’s stock.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc and related companies with MarketBeat.com's FREE daily email newsletter.